If you have been reading about freeze-dried powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-24. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
The YES/YAS assay is performed in 96-well microtiter plates. Total assay time is usually 2–3 days, but faster protocols (18 hrs. exposure time) using induced cell lysis have been developed. Several yeast cell lines have been developed for the YES and YAS assay, both proprietary and publicly available. Commercial kits with all necessary ingredients and detailed instructions are also available. Substances with an activating or inhibitory effect on the estrogen and/or androgen receptor of organisms may interfere with reproduction, affect the metabolism and immune system and induce the formation of tumors. This assay is suitable for detecting numerous natural and synthetic hormonally active substances such as environmental toxins from everyday products, e.g. birth control pill ingredients (17α-ethinylestradiol), synthetic materials (bisphenol A, phthalates), pesticides (methoxychlorine) and non-ionic surfactants (alkylphenols). The test has a good reproducibility and concordance with literature data of in vivo or in vitro data.
== History == In 1968, Josef Pacák, Zdeněk Točík, and Miloslav Černý at the Department of Organic Chemistry, Charles University, Czechoslovakia were the first to describe the synthesis of FDG. Later, in the 1970s, Tatsuo Ido and Al Wolf at the Brookhaven National Laboratory were the first to describe the synthesis of FDG labeled with fluorine-18. The compound was first administered to two human volunteers by Abass Alavi in August 1976 at the University of Pennsylvania. Brain images obtained with an ordinary (non-PET) nuclear scanner demonstrated the concentration of [18F]FDG in that organ (see history reference below). Beginning in August 1990, and continuing throughout 1991, a shortage of oxygen-18, a raw material for FDG, made it necessary to ration isotope supplies. Israel's oxygen-18 facility had shut down due to the Gulf War, and the U.S. government had shut down its isotopes of carbon, oxygen and nitrogen facility at Los Alamos National Laboratory, leaving Isotec as the main supplier.
=== African-American communities === The war on drugs has incarcerated high numbers of African-Americans. However, the damage has compounded beyond individuals to affect African-American communities as a whole, with some social scientists suggesting the war on drugs could not be maintained without societal racism and the manipulation of racial stereotypes. African-American children are overrepresented in juvenile hall and family court cases, a trend that began during the war on drugs. From 1985 to 1999, admissions of blacks under the age of 18 increased by 68%. Some authors posit that the overrepresentation is caused by minority juveniles committing crime more often and more serious crimes. A compounding factor is often the imprisonment of a father. Boys with imprisoned fathers are significantly less likely to develop the skills necessary for success in early education. In addition, African-American youth often turn to gangs to generate income for their families, oftentimes more effectively than at a minimum wage or entry-level job. Still, this occurs even as substance abuse, especially marijuana, has largely declined among high school students. In contrast, many black youths drop out of school, are subsequently tried for drug-related crime, and acquire AIDS at disparate levels. In addition, the high incarceration rate has led to the juvenile justice system and family courts to use race as a negative heuristic in trials, leading to a reinforcing effect.
From Donald Trump's reelection in 2024 and until his public reversal in January 2026, he refused to rule out an invasion of Greenland and engaged in actions and comments seen as provocations against Denmark. Danish national broadcaster DR divided Trump's plans to take over Greenland into three main phases, starting from December 2024: a charm offensive, pressure on the Danish government, and Greenlandic societal infiltration.
Sources: en.wikipedia.org
The rhinoceros viper (Bitis nasicornis) is a large species of viper that is similar to the Gaboon viper, but not as venomous, smaller and with a less dangerous bite. They are slow moving, but like other Bitis species, they're capable of striking quickly, forwards or sideways, without coiling first or giving a warning. Holding them by the tail is not safe; as it is somewhat prehensile, they can use it to fling themselves upwards and strike. They have been described as generally placid creatures, not as bad-tempered as the Puff adder. When approached, they often reveal their presence by hissing, said to be the loudest hiss of any African snake – almost a shriek. Relatively little is known about the toxicity and composition of the venom, but it has very minor neurotoxic, as well as hemotoxic venom, as do most other venomous snakes. The hemotoxic venom in rhinoceros vipers is much more dominant. This venom attacks the circulatory system of the snake's victim, destroying tissue and blood vessels. Internal bleeding also occurs. In mice, the intravenous LD50 is 1.1 mg/kg. The venom is supposedly slightly less toxic than those of the Puff adder and the Gaboon viper. The maximum wet venom yield is 200 mg. In only a few detailed reports of human envenomation, massive swelling, which may lead to necrosis, had been described. In 2003, a man in Dayton, Ohio, who was keeping a specimen as a pet, was bitten and subsequently died. At least one antivenom protects specifically against bites from this species: India Antiserum Africa Polyvalent.
== Capture of Constantinople == When the Nicaean force reached the village of Selymbria, some 30 miles (48 km) west of Constantinople, they learned from some independent local farmers (thelematarioi) that the entire Latin garrison, as well as the Latin-allied Venetian fleet, was absent conducting a raid against the Nicaean island of Daphnousia in the Black Sea. Strategopoulos initially hesitated to take advantage of the situation, fearing that his small force might be destroyed if the Latin army returned too soon, and because he would exceed the provisions of the emperor's orders, but eventually decided he could not squander such a remarkable opportunity to seize the city without a prolonged siege.
==== 3.A. P-P-bond hydrolysis-driven transporters ==== 3.A.1 ABC transporters including BtuCD, molybdate uptake transporter, Cystic fibrosis transmembrane conductance regulator and others 3.A.2 The H+- or Na+-translocating F-type ATPase, V-type ATPase and A-type ATPase superfamily 3.A.3 The P-type ATPase Superfamily 3.A.4 The Arsenite-Antimonite efflux family 3.A.5 General secretory pathway (Sec) translocon (preprotein translocase SecY) 3.A.6 The Type III (Virulence-related) Secretory Pathway (IIISP) Family 3.A.7 The Type IV (Conjugal DNA-Protein Transfer or VirB) Secretory Pathway (IVSP) Family 3.A.8 The Mitochondrial Protein Translocase (MPT) Family 3.A.9 The Chloroplast Envelope Protein Translocase (CEPT or Tic-Toc) Family 3.A.10 H+, Na+-translocating Pyrophosphatase family 3.A.11 The Bacterial Competence-related DNA Transformation Transporter (DNA-T) Family 3.A.12 The Septal DNA Translocator (S-DNA-T) Family 3.A.13 The Filamentous Phage Exporter (FPhE) Family 3.A.14 The Fimbrilin/Protein Exporter (FPE) Family 3.A.15 The Outer Membrane Protein Secreting Main Terminal Branch (MTB) Family 3.A.16 The Endoplasmic Reticular Retrotranslocon (ER-RT) Family 3.A.17 The Phage T7 Injectisome (T7 Injectisome) Family 3.A.18 The Nuclear mRNA Exporter (mRNA-E) Family 3.A.19 The TMS Recognition/Insertion Complex (TRC) Family 3.A.20 The Peroxisomal Protein Importer (PPI) Family 3.A.21 The C-terminal Tail-Anchored Membrane Protein Biogenesis/ Insertion Complex (TAMP-B) Family 3.A.22 The Transcription-coupled TREX/TAP Nuclear mRNA Export Complex (TREX) Family 3.A.23 The Type VI Symbiosis/Virulence Secretory Pathway (VISP) Family 3.A.24 Type VII or ESX Protein Secretion System (T7SS) Family 3.A.25 The Symbiont-specific ERAD-like Machinery (SELMA) Family 3.A.26 The Plasmodium Translocon of Exported proteins (PTEX) Family
=== Länder in East Germany === In the Soviet occupation zone, five Länder were established which roughly corresponded to the preexisting states and provinces. (The territories east of the Oder–Neisse line had been transferred from the Soviet occupation zone to the Polish authorities as agreed upon at the Potsdam Conference.) The five states were:
=== Transmission === The reason for this increased HBV infection is unknown, because hepatitis B has no clear transmission routes in many people in China, although both neonatal infection and horizontal transmission during early childhood are still the most common routes. During and before the Cultural revolution many of the cases came from re-used needles that were contaminated with HBV.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.